# Poolbeg Pharma Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-positive-outputs-from-lab-based-analysis-of-rsv-drug-candidates-identified-using-ai/4121136614
- Published: 2023-12-20T07:09:59+00:00
- Author: Ethan Davis

**Poolbeg Pharma** ([LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation
of innovative medicines targeting diseases with a high unmet medical need, has announced
the positive outputs from the lab-based analysis and successful prioritisation of
the Respiratory Syncytial Virus (‘RSV’) drug targets and treatments identified as
part of its artificial intelligence (‘AI’) led programme.

Poolbeg’s team of scientific experts have reviewed the comprehensive data package
obtained from this lab-based analysis and has strategically prioritised a select
number of the RSV drug candidates that were analysed. The Company is actively exploring
the most effective way to progress the prioritised drug candidates in order to generate
value. Poolbeg believes the data obtained reflects the high potential of this AI-
led programme and supports its partnering efforts.

The global interest in AI-led drug discovery continues to grow, with major pharmaceutical
players making substantial investments in the field. Poolbeg’s RSV AI programme 
identified these drug treatment candidates in just 10 months. AI-led drug discovery
can accelerate the timeline achievable which reduces costs while also decreasing
risks and providing a higher likelihood of success in bringing groundbreaking therapies
to patients.

**Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented:**_“
The positive outputs from this analysis, and the successful prioritisation of our
RSV drug candidates, is a testament to the power of our AI-led drug discovery programme.
As we engage in partnering discussions, these results position Poolbeg as a key 
player in the evolving landscape of AI-driven drug discovery.”_

[Poolbeg Pharma plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)
is committed to the development and commercialisation of innovative medicines targeting
diseases with a high unmet medical need. Its model focusses upon developing its 
exciting clinical assets and commercialising approved and marketed drugs to fund
the development of its robust pipeline of innovative products, thereby driving significant
value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant
shareholder value. The team has been strengthened by the appointment of three former
members of the Amryt Pharma plc leadership team, with the intention of repeating
Amryt’s success and generating near term revenues.

Poolbeg’s clinical programmes target large addressable markets including CRS induced
by cancer immunotherapies, infectious disease, and metabolic conditions such as 
obesity with the development of an oral GLP-1R agonist. It uses a cost-effective
development philosophy to generate high quality human data to support partnering
and further development. Its AI-led infectious disease programmes analyse unique
data from human challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial appeal. 

Respiratory Syncytial Virus (RSV) which inflames the smallest airways of the lungs,
sends an average of 58,000-80,000 children under the age of five to hospital each
year in the US alone, according to the US Centers for Disease Control and Prevention(
CDC). RSV can also be dangerous for adults over the age of 65, resulting in around
177,000 hospitalisations per year in the United States alone. 

Share on:
